MAM
REGN icon

Mark Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Mark Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,989
Closed -$1.11M – 77
2020
Q3 		$1.11M Sell
1,989
-12
-0.6% -$7.28K 0.16% 53
2020
Q2 		$1.25M Buy
+2,001
New +$1.14M 0.24% 47

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Mark Asset Management's REGN Position: Q4 2020 in Review

Mark Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 1,989 shares — an estimated $1.11M sold.

Mark Asset Management first reported a position in REGN in Q2 2020 and held it in 2 quarters. The position peaked at $1.25M in Q2 2020. 903 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

  • Mark Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Mark Asset Management sold 1,989 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $1.11M.
  • Mark Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Mark Asset Management's Regeneron Pharmaceuticals position peaked at $1.25M in Q2 2020.
  • 903 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Mark Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.